| Literature DB >> 27199429 |
Till Schoofs1, Florian Klein2, Malte Braunschweig3, Edward F Kreider4, Anna Feldmann5, Lilian Nogueira1, Thiago Oliveira1, Julio C C Lorenzi1, Erica H Parrish4, Gerald H Learn4, Anthony P West6, Pamela J Bjorkman6, Sarah J Schlesinger1, Michael S Seaman7, Julie Czartoski8, M Juliana McElrath8, Nico Pfeifer5, Beatrice H Hahn4, Marina Caskey1, Michel C Nussenzweig9.
Abstract
3BNC117 is a broad and potent neutralizing antibody to HIV-1 that targets the CD4 binding site on the viral envelope spike. When administered passively, this antibody can prevent infection in animal models and suppress viremia in HIV-1-infected individuals. Here we report that HIV-1 immunotherapy with a single injection of 3BNC117 affects host antibody responses in viremic individuals. In comparison to untreated controls that showed little change in their neutralizing activity over a 6-month period, 3BNC117 infusion significantly improved neutralizing responses to heterologous tier 2 viruses in nearly all study participants. We conclude that 3BNC117-mediated immunotherapy enhances host humoral immunity to HIV-1.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27199429 PMCID： PMC5151174 DOI： 10.1126/science.aaf0972
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728